{"id":355493,"date":"2026-11-19T15:08:35","date_gmt":"2026-11-19T09:38:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355493"},"modified":"2026-11-19T15:08:35","modified_gmt":"2026-11-19T09:38:35","slug":"dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/","title":{"rendered":"Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Dr_Lal_PathLabs_Share_Price_134_CAGR_in_3_Years_as_the_Delhi-Based_Diagnostics_Chain_Compares_With_Metropolis_Healthcare_Apollo_Hospitals_and_Max_Healthcare\" title=\"Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare\">Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#How_Much_Has_the_Dr_Lal_PathLabs_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Dr Lal PathLabs Share Price Returned in 3 Years?\">How Much Has the Dr Lal PathLabs Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Dr_Lal_PathLabs_vs_Metropolis_Healthcare_Apollo_Hospitals_and_Max_Healthcare_3-Year_CAGR_Compared\" title=\"Dr Lal PathLabs vs Metropolis Healthcare, Apollo Hospitals and Max Healthcare: 3-Year CAGR Compared\">Dr Lal PathLabs vs Metropolis Healthcare, Apollo Hospitals and Max Healthcare: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#What_Is_Driving_the_Dr_Lal_PathLabs_Stock\" title=\"What Is Driving the Dr Lal PathLabs Stock?\">What Is Driving the Dr Lal PathLabs Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#How_to_Compare_Diagnostics_Stocks_Yourself\" title=\"How to Compare Diagnostics Stocks Yourself\">How to Compare Diagnostics Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#A_Diagnostics_Chain_Beside_One_Peer_and_Two_Hospital_Chains\" title=\"A Diagnostics Chain Beside One Peer and Two Hospital Chains\">A Diagnostics Chain Beside One Peer and Two Hospital Chains<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#What_is_the_Dr_Lal_PathLabs_share_price_today\" title=\"What is the Dr Lal PathLabs share price today?\">What is the Dr Lal PathLabs share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#What_is_the_3-year_CAGR_of_the_Dr_Lal_PathLabs_stock\" title=\"What is the 3-year CAGR of the Dr Lal PathLabs stock?\">What is the 3-year CAGR of the Dr Lal PathLabs stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Is_Dr_Lal_PathLabs_better_than_Metropolis\" title=\"Is Dr Lal PathLabs better than Metropolis?\">Is Dr Lal PathLabs better than Metropolis?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#What_does_Dr_Lal_PathLabs_do\" title=\"What does Dr Lal PathLabs do?\">What does Dr Lal PathLabs do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Is_the_Dr_Lal_PathLabs_stock_debt_free\" title=\"Is the Dr Lal PathLabs stock debt free?\">Is the Dr Lal PathLabs stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Is_Dr_Lal_PathLabs_expensive_compared_with_the_industry\" title=\"Is Dr Lal PathLabs expensive compared with the industry?\">Is Dr Lal PathLabs expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#Which_diagnostics_stock_gave_the_highest_return_in_3_years\" title=\"Which diagnostics stock gave the highest return in 3 years?\">Which diagnostics stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-share-price-3-year-cagr-vs-diagnostics-peers-metropolis-apollo-hospitals-max-healthcare\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Share_Price_134_CAGR_in_3_Years_as_the_Delhi-Based_Diagnostics_Chain_Compares_With_Metropolis_Healthcare_Apollo_Hospitals_and_Max_Healthcare\"><\/span><strong>Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years as the Delhi-Based Diagnostics Chain Compares With Metropolis Healthcare, Apollo Hospitals and Max Healthcare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dr Lal PathLabs previous close Rs 1,965.40. 3-year CAGR 13.4%. Up 1.5x since 17 Nov 2023. ROE 21.32%. Market cap Rs 32,976 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Dr Lal PathLabs share price<\/strong> closed at Rs 1,965.40 on 18 November 2026, a compounded annual return of <strong>13.4%<\/strong> over three years. That compares with Metropolis Healthcare at 11.8%, Apollo Hospitals at 17.2% and Max Healthcare at 18.9%. The company has a <strong>market cap<\/strong> of Rs 32,976 crore and a P\/E of 56.08 against an industry P\/E of 63.96.<\/p>\n<\/p><\/div>\n<p>The <strong>Dr Lal PathLabs share price<\/strong> closed at Rs 1,965.40 on 18 November 2026 and has compounded at <strong>13.4%<\/strong> a year over three years. Dr Lal PathLabs, based in Delhi, runs a network of <strong>diagnostic labs<\/strong> and collection centres that offer blood tests, imaging and health packages.<\/p>\n<p>This article places that return beside Metropolis Healthcare, Apollo Hospitals and Max Healthcare. We calculate the <strong>three-year CAGR<\/strong> for all four and set the results next to market cap, valuation, <strong>return on equity<\/strong> and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=dr-lal-pathlabs-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Dr_Lal_PathLabs_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Dr Lal PathLabs Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Dr Lal PathLabs stock<\/strong> closed at Rs 1,349.38 on 17 November 2023 and at Rs 1,965.40 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.46 lakh, which is a <strong>CAGR<\/strong> of <strong>13.4%<\/strong>. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Dr Lal PathLabs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>Diagnostics companies earn steady volumes because tests are repeat and referral driven. The <strong>Dr Lal PathLabs share price<\/strong> reflects that pattern, with returns built on test volume growth and a strong balance sheet.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Metropolis_Healthcare_Apollo_Hospitals_and_Max_Healthcare_3-Year_CAGR_Compared\"><\/span><strong>Dr Lal PathLabs vs Metropolis Healthcare, Apollo Hospitals and Max Healthcare: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 17 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (18 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Max Healthcare<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 607.75<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,022.85<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.7x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Apollo Hospitals<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 5,478.95<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 8,821.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Dr Lal PathLabs<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,349.38<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,965.40<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.5x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">13.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Metropolis Healthcare<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 404.35<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 564.30<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.4x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">11.8%<\/td>\n<\/tr>\n<\/table>\n<p>The <strong>Dr Lal PathLabs stock<\/strong> ranks third of the four at <strong>13.4%<\/strong>. It sits ahead of Metropolis Healthcare (11.8%). The companies ahead are Max Healthcare (18.9%) and Apollo Hospitals (17.2%). By market cap the company ranks third of the four at Rs 32,976 crore. Apollo Hospitals is the largest of the four by market cap, while Dr Lal PathLabs is a pure diagnostics business.<\/p>\n<p>Look at the <strong>Dr Lal PathLabs share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/apollohosp\/apollo-hospitals-enterprise-ltd-share-price-today\">Apollo Hospitals<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,26,689 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">54.20<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">63.96<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.14%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.77<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/maxhealth\/max-healthcare-institute-ltd-share-price-today\">Max Healthcare<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 99,474 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">72.07<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">63.96<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">12.18%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.33<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 32,976 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">56.08<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">63.96<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.32%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.09<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/metropolis\/metropolis-healthcare-ltd-share-price-today\">Metropolis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 11,704 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">51.93<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">63.96<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">13.66%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.16<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Apollo Hospitals is the largest of the group at Rs 1,26,689 crore, while the Dr Lal PathLabs stock stands at Rs 32,976 crore, about 26% of that size. On earnings, Dr Lal PathLabs shares trade at a P\/E of 56.08 against an industry P\/E of 63.96, a discount of about 12% to the sector, which leaves room if earnings keep growing. Peer multiples are Metropolis Healthcare at 51.93, Apollo Hospitals at 54.20 and Max Healthcare at 72.07.<\/p>\n<p>Return on equity is 21.32% for the Dr Lal PathLabs stock, which ranks first among the four, and <strong>debt to equity<\/strong> stands at 0.09. Trailing EPS is Rs 35.03. Dr Lal PathLabs trades at a P\/E of 56.08 against an industry P\/E of 63.96, with a price to book of 12.02. The ROE of 21.32% is the highest in the group.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Dr_Lal_PathLabs_Stock\"><\/span><strong>What Is Driving the Dr Lal PathLabs Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Lal PathLabs earns revenue from routine and specialised tests, <strong>wellness packages<\/strong> and home collection. A large lab network and a wide collection reach help it add test volumes with limited extra spending.<\/p>\n<p>The company earns an ROE of 21.32% and carries a debt to equity of just 0.09, which is the lowest in the group. Its P\/E of 56.08 sits below the industry P\/E of 63.96.<\/p>\n<p>Investors who follow the <strong>Dr Lal PathLabs share price<\/strong> usually track growth in test volumes, revenue per patient, the share of wellness packages and operating margin.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Metropolis Healthcare is a Mumbai-based diagnostics chain with labs and collection centres across India. It compounded at 11.8% a year, on a market cap of Rs 11,704 crore and an ROE of 13.66%.<\/p>\n<p>Apollo Hospitals is a Chennai-based hospital chain with a pharmacy and digital health arm. It compounded at 17.2% a year, on a market cap of Rs 1,26,689 crore and an ROE of 21.14%.<\/p>\n<p>Max Healthcare is a hospital chain with multi-speciality hospitals across several Indian cities. It compounded at 18.9% a year, on a market cap of Rs 99,474 crore and an ROE of 12.18%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Dr Lal PathLabs share price<\/strong>. First, growth in test volumes in the next quarterly result. Second, the share of wellness and specialised tests. Third, operating margin as new labs open.<\/p>\n<p>At a P\/E of 56.08 the stock trades below the industry P\/E of 63.96, which leaves room if volumes keep growing. Competition from other lab chains can affect pricing, so follow each result closely.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of diagnostics stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Diagnostics_Stocks_Yourself\"><\/span><strong>How to Compare Diagnostics Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Dr Lal PathLabs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Dr Lal PathLabs share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Dr Lal PathLabs share price<\/strong> and compare diagnostics stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"A_Diagnostics_Chain_Beside_One_Peer_and_Two_Hospital_Chains\"><\/span><strong>A Diagnostics Chain Beside One Peer and Two Hospital Chains<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Dr Lal PathLabs share price<\/strong> compounded at 13.4% a year over three years, against 11.8% for Metropolis, 17.2% for Apollo Hospitals and 18.9% for Max Healthcare. Its ROE of 21.32% and debt to equity of 0.09 add to the quality case.<\/p>\n<p>Max Healthcare brings the fastest return, Dr Lal PathLabs brings the highest ROE and Metropolis Healthcare brings the lowest P\/E. Dr Lal PathLabs offers a light balance sheet and a pure diagnostics focus.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Dr_Lal_PathLabs_share_price_today\"><\/span><strong>What is the Dr Lal PathLabs share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs closed at Rs 1,965.40 on 18 November 2026, according to NSE data. It has a market cap of Rs 32,976 crore and a P\/E of 56.08. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Dr_Lal_PathLabs_stock\"><\/span><strong>What is the 3-year CAGR of the Dr Lal PathLabs stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs delivered a price CAGR of 13.4% over three years, moving from Rs 1,349.38 on 17 November 2023 to Rs 1,965.40 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dr_Lal_PathLabs_better_than_Metropolis\"><\/span><strong>Is Dr Lal PathLabs better than Metropolis?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs delivered the higher three-year CAGR at 13.4% against 11.8% for Metropolis. Dr Lal PathLabs has the larger market cap at Rs 32,976 crore against Rs 11,704 crore for Metropolis. Dr Lal PathLabs earns the higher ROE at 21.32% against 13.66%. Metropolis trades at the lower P\/E of 51.93 against 56.08. The better choice depends on whether you weigh recent return, size, profitability or valuation most.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Dr_Lal_PathLabs_do\"><\/span><strong>What does Dr Lal PathLabs do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs Limited is a Delhi-based diagnostics company that runs laboratories, collection centres and home sample collection services across India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Dr_Lal_PathLabs_stock_debt_free\"><\/span><strong>Is the Dr Lal PathLabs stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Dr Lal PathLabs stock is 0.09 and its return on equity is 21.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dr_Lal_PathLabs_expensive_compared_with_the_industry\"><\/span><strong>Is Dr Lal PathLabs expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs trades at a P\/E of 56.08 against an industry P\/E of 63.96. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_diagnostics_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which diagnostics stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Max Healthcare delivered the highest three-year CAGR at 18.9%, followed by Apollo Hospitals at 17.2%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Dr Lal PathLabs share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs closed at Rs 1,965.40 on 18 November 2026, according to NSE data. It has a market cap of Rs 32,976 crore and a P\/E of 56.08. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Dr Lal PathLabs stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs delivered a price CAGR of 13.4% over three years, moving from Rs 1,349.38 on 17 November 2023 to Rs 1,965.40 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Dr Lal PathLabs better than Metropolis?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs delivered the higher three-year CAGR at 13.4% against 11.8% for Metropolis. Dr Lal PathLabs has the larger market cap at Rs 32,976 crore against Rs 11,704 crore for Metropolis. Dr Lal PathLabs earns the higher ROE at 21.32% against 13.66%. Metropolis trades at the lower P\/E of 51.93 against 56.08. The better choice depends on whether you weigh recent return, size, profitability or valuation most.\"}},{\"@type\":\"Question\",\"name\":\"What does Dr Lal PathLabs do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs Limited is a Delhi-based diagnostics company that runs laboratories, collection centres and home sample collection services across India.\"}},{\"@type\":\"Question\",\"name\":\"Is the Dr Lal PathLabs stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Dr Lal PathLabs stock is 0.09 and its return on equity is 21.32%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Dr Lal PathLabs expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs trades at a P\/E of 56.08 against an industry P\/E of 63.96. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which diagnostics stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Max Healthcare delivered the highest three-year CAGR at 18.9%, followed by Apollo Hospitals at 17.2%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Lal PathLabs share price compounded at 13.4% a year over 3 years. See how it compares with peers on returns and valuation.<\/p>\n","protected":false},"author":38,"featured_media":355492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[26365,26362,26364,26363],"class_list":["post-355493","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-diagnostics-stocks-3-year-return","tag-dr-lal-pathlabs-share-price","tag-dr-lal-pathlabs-stock","tag-dr-lal-pathlabs-vs-metropolis"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355492"],"rank_math_title":["Dr Lal PathLabs Share Price: 13.4% CAGR in 3 Years"],"rank_math_description":["Dr Lal PathLabs share price compounded at 13.4% a year over 3 years. See how it compares with peers on returns and valuation."],"rank_math_focus_keyword":["Dr Lal PathLabs share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/dr-lal-pathlabs-share-price-13-4-cagr-in-3-years-as-the-delhi-based-diagnostics.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355493"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355493\/revisions"}],"predecessor-version":[{"id":355494,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355493\/revisions\/355494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355492"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}